Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Xalkori
Biotech
Nuvalent trots out strong pivotal data in FDA lung cancer push
Nuvalent is eyeing an FDA rolling submission for its ROS1 inhibitor in TKI-pretreated lung cancer after releasing competitive pivotal data.
Angus Liu
Jun 24, 2025 6:30am
Turning Point posts data on Rozlytrek rival
Aug 20, 2020 9:15am
Xcovery's Xalkori challenger shines in phase 3
Aug 8, 2020 7:00am
Ignyta NSCLC durability data set stage for Pfizer fight
Oct 18, 2017 9:26am
Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial
Oct 16, 2017 9:55am
ROS1 cancer patients set out to create disease models
Aug 15, 2017 8:55am
